Tildrakizumab & Ixekizumab

VIENNA – Tildrakizumab, a novel biologic for moderate to severe psoriasis, showed favorable efficacy and safety outcomes in two pivotal…
mdedge.com

Like Guselkumab, Tildrakizumab binds the p13 subunit, thus inhibiting IL23 specifically.
Like Ustekinumab (anti-IL12/23), it is given subcutaneously every 3 months after the first 2 doses are given a month apart.
Just as Guselkumab compared favorably against Adalimumab (anti-TNF) in Psoriasis, Tildrakizumab trumped Etanercept (anti-TNF). The fantastic skin score responses place it in the league of Guselkumab and Secukinumab (anti-IL17A).
Safety data appeared homogenously good among the biologics targeting the Th17 pathway.
However, time to peak efficacy paled to Guselkumab and Secukinumab. Perhaps it should have intensified the dosing interval in the first month of loading, like what was done for Secukinumab.


Ixekizumab Success with the UNCOVER Trials in Psoriasis

The NEJM today published the results of two…
rheumnow.com

Ixekizumab Superior to Etanercept in Psoriasis

The UNCOVER-2 and UNCOVER-3 trials were presented at the American Academy of Dermatology (AAD) Annual Meeting taking this week in Washington, D.C.
rheumnow.com